# ACORN CAPITAL ADVISORS, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2054410. Source: https://holderbook.com/funds/2054410-acorn-capital-advisors-llc/

- Reported value: $366.5M
- Positions: 20
- Weight of the ten largest: 90.2%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $80.4M | 1,131,500 | 21.9% | 7 |
| UROGEN PHARMA LTD | [URGN](https://holderbook.com/stocks/URGN/) | $61.6M | 1,673,420 | 16.8% | 7 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $40.0M | 2,144,844 | 10.9% | 7 |
| CANDEL THERAPEUTICS INC | [CADL](https://holderbook.com/stocks/CADL/) | $36.0M | 3,497,948 | 9.8% | 7 |
| PUMA BIOTECHNOLOGY INC | [PBYI](https://holderbook.com/stocks/PBYI/) | $33.5M | 4,131,299 | 9.1% | 7 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $21.9M | 986,760 | 6.0% | 2 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $19.1M | 643,381 | 5.2% | 7 |
| KARYOPHARM THERAPEUTICS INC | [KPTI](https://holderbook.com/stocks/KPTI/) | $14.8M | 1,518,113 | 4.0% | 2 |
| ONKURE THERAPEUTICS INC | [OKUR](https://holderbook.com/stocks/OKUR/) | $12.9M | 2,839,674 | 3.5% | 7 |
| CYBIN INC | [HELP](https://holderbook.com/stocks/HELP/) | $10.2M | 1,540,266 | 2.8% | 7 |
| PROTARA THERAPEUTICS INC | [TARA](https://holderbook.com/stocks/TARA/) | $6.7M | 1,752,115 | 1.8% | 7 |
| AURA BIOSCIENCES INC | [AURA](https://holderbook.com/stocks/AURA/) | $6.6M | 929,077 | 1.8% | 6 |
| LEONABIO INC | [LONA](https://holderbook.com/stocks/LONA/) | $5.8M | 634,539 | 1.6% | 3 |
| VERASTEM INC | [VSTM](https://holderbook.com/stocks/VSTM/) | $5.6M | 1,469,153 | 1.5% | 7 |
| WHITEHAWK THERAPEUTICS INC | [WHWK](https://holderbook.com/stocks/WHWK/) | $5.2M | 1,139,363 | 1.4% | 7 |
| Q32 BIO INC | [QTTB](https://holderbook.com/stocks/QTTB/) | $2.8M | 216,171 | 0.8% | 7 |
| Engene Therapeutics Inc | [ENGN](https://holderbook.com/stocks/ENGN/) | $2.2M | 1,271,257 | 0.6% | 1 |
| JASPER THERAPEUTICS INC | [JSPR](https://holderbook.com/stocks/JSPR/) | $604.0K | 1,438,159 | 0.2% | 4 |
| BIOATLA INC | [BCAB](https://holderbook.com/stocks/BCAB/) | $447.6K | 108,126 | 0.1% | 7 |
| VYNE THERAPEUTICS INC | [VYNE](https://holderbook.com/stocks/VYNE/) | $926 | 1,425 | 0.0% | 7 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +35.2% | +14.8% | +20.3% | 73% |
| Q1 2026 | +12.5% | -4.6% | +17.1% | 100% |
| Q4 2025 | +44.5% | +2.4% | +42.2% | 100% |
| Q3 2025 | +40.7% | +7.8% | +32.9% | 90% |
| Q2 2025 | +1.1% | +10.5% | -9.3% | 98% |
| Q1 2025 | -24.0% | -4.6% | -19.5% | 103% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $366.5M | 20 |
| Q1 2026 | $351.8M | 22 |
| Q4 2025 | $295.1M | 21 |
| Q3 2025 | $197.0M | 20 |
| Q2 2025 | $152.9M | 21 |
| Q1 2025 | $149.9M | 22 |
| Q4 2024 | $185.8M | 21 |